Pregled bibliografske jedinice broj: 440931
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis // Clinical rheumatology, 29 (2010), 5; 487-493 doi:10.1007/s10067-009-1345-2 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 440931 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis
Autori
Tešija-Kuna, Andrea ; Grazio, Simeon ; Miler, Marijana ; Vukasović, Ines ; Perić, Porin ; Vrkić, Nada
Izvornik
Clinical rheumatology (0770-3198) 29
(2010), 5;
487-493
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
antibodies against mutated citrullinated vimentin; antibodies targeting citrullinated peptides; psoriatic arthritis
Sažetak
Antibodies against mutated citrullinated vimentin (anti-MCV) are of a comparable diagnostic value in rheumatoid arthritis (RA) as antibodies targeting citrullinated peptides (anti-CCP). Anti-CCP are present in up to 15% of psoriatic arthritis (PsA) patients, while the prevalence of anti-MCV in PsA patients has been poorly investigated. The aim of the present study was to assess the prevalence and relevance of anti-MCV antibodies in PsA patients. The study included 56 PsA patients. Clinical features, disease activity, and functional ability were noted by an experienced rheumatologist. Serum samples of all patients were analyzed for anti-MCV and anti-CCP antibodies using enzyme-linked immunosorbent assay. Data on 92 patients with RA, 44 patients with other inflammatory rheumatic diseases, and 107 healthy controls from a previous study were used to compare the prevalence of anti- MCV antibodies in PsA patients. Anti-MCV antibodies were positive in only two out of 56 (3.6%) PsA patients, which was significantly lower compared to RA patients (63%). The anti-MCV level was moderately positive and borderline in one patient each. Both patients had asymmetric polyarthritis, dactylitis, moderate to high disease activity, and were anti-CCP and rheumatoid factor (RF) negative. There was no significant difference in anti-MCV levels according to clinical subtypes of PsA and no correlation of anti-MCV levels with anti-CCP, RF, disease activity variables, and functional ability indices. According to study results, anti-MCV antibodies can be detected in a very small proportion of PsA patients with polyarthritic disease and are primarily related to the polyarthritic pattern rather than the specific diagnosis of RA.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
108-0000000-0164 - Nove metode u dijagnostici i liječenju bolesti i ozljeda ramena (Čičak, Nikola, MZOS ) ( CroRIS)
134-0000000-3531 - Psorijatični artritis - epidemiologija i čimbenici rizika progresije (Grazio, Simeon, MZOS ) ( CroRIS)
134-0061245-0205 - Hemoreološki poremećaji u kroničnim bolestima (Vrkić, Nada, MZOS ) ( CroRIS)
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Šimundić, Ana-Maria, MZOS ) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb
Profili:
Andrea Tešija Kuna
(autor)
Simeon Grazio
(autor)
Ines Vukasović
(autor)
Marijana Miler
(autor)
Nada Vrkić
(autor)
Porin Perić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- MEDLINE